Vantage logo

Neptune leaves Astra at sea

The Neptune lung cancer study fails, denting yet further Astrazeneca and Bristol-Myers Squibb’s chances of challenging Merck & Co’s Keytruda on the basis of tumour…

Vantage logo

Reality bites for Macrogenics 

Hopes are fading for margetuximab in breast cancer, which looks unlikely to show an overall survival benefit in the Sophia study.